BridgeBio Oncology Therapeutics Inc Com
Research BridgeBio Oncology Therapeutics Inc Com (BBOT) on Bullrun: market cap USD 265.18M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBBOT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 265.18M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 56.45M
- Free cash flow-USD 44.41M
Valuation Snapshot
latest market cap is USD 265.18M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 134.04M | -USD 114.50M | n/a | -4.3 | USD 373.69M | USD 2.77M | USD 411.10M |
| FY2024 | USD 0 | -USD 74.28M | -USD 55.08M | n/a | -5756.41 | USD 30.85M | USD 0 | -USD 178.64M |
| FY2023 | USD 0 | -USD 41.69K | -USD 52.49M | n/a | -0.82 | USD 250.00K | n/a | -USD 115.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 265.18M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.00B | n/a | n/a | n/a |
| 2024 | 2024-09-27 | n/a | 74.6 | n/a | n/a |
About BridgeBio Oncology Therapeutics Inc Com
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BridgeBio Oncology Therapeutics Inc Com's market cap?
BridgeBio Oncology Therapeutics Inc Com's market capitalization is USD 265.18M.
What does BridgeBio Oncology Therapeutics Inc Com do?
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.